Analystreport

Arbutus Biopharma (NASDAQ: ABUS) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock.

Arbutus Biopharma Corporation  (ABUS) 
Last arbutus biopharma corporation earnings: 11/6 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.arbutusbio.com/node/5806